Identifying Markers of Disease Subtypes and Disease Progression in the Syndrome of Essential Tremor

Sponsor
Medical University of Graz
Study ID
NCT06349538
Status
Enrolling By Invitation

Conditions

  • Essential Tremor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Clinical examination, blood draw, cerebral MRI, sonography, tremor analysis, OCT, olfactory mucosa swab. — DIAGNOSTIC_TEST
    see previous descriptions

Study Details

The goal of this observational study is to learn about epidemiology, biologic markers, disease subtypes and possible prognostic factors in essential tremor (ET) patients. The main question\[s\] it aims to answer are: * The prevalence of ET-plus compared to ET in a prospectively collected ET population. * To assess in detail the heterogenous group of ET patients using comprehensive clinical (motor and non-motor scales, questionnaires), imaging \[magnetic resonance imaging (MRI), sonography of substantia nigra and cerebral vessels\], neurophysiological (tremor analysis, digital spiral drawing) and laboratory markers (sGFAP, sNfL, routine laboratory parameters). * To assess possible non-invasive markers of neurodegeneration in ET patients (optic coherence tomography, alpha-synuclein in olfactory mucosa) Participants will be asked to undergo the above mention evaluation at baseline and at follow-up approx. 5 years later. Researchers will compare the findings within the ET group to independently existing cohorts of healthy controls and/or patients with other movement disorders like Parkinson's disease.

Key Dates

First listed
Apr 5, 2024
Start date
Apr 4, 2024
Status verified
Sep 2025
Primary completion
Apr 30, 2026
Completion
Apr 30, 2034

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Essential tremor patients
    Essential tremor patients will undergo a detailed clinical examination incl. motor/non motor scoring systems and questionnaires, blood draw, sonography, tremor analysis and cerebral MRI. Additionally, essential tremor patients will undergo optic coherence tomography and olfcatory mucosa swab for alpha-synuclein. All tests are conducted at baseline as well as at a follow-up examination 5 years later. No drugs or other interventions are to be administered

Primary Outcome Measure

Prevalence of ET-plus [ Time Frame: approx. 2 years ]

Related Studies